 Nabriva Therapeutics plc NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 4, at 1:00p.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETATM lefamulin injection, lefamulin tablets, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia CABP. 